Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells

Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells

Abstract Background Tamoxifen resistance presents a huge clinical challenge for breast cancer patients. An understanding of the mechanisms of tamoxifen resistance can guide development of efficient therapies to prevent drug resistance. Methods We first tested whether peptidylarginine deiminase 2 (PA...

Full description

Bibliographic Details
Main Authors: Fujun Li, Lixia Miao, Teng Xue, Hao Qin, Santanu Mondal, Paul R. Thompson, Scott A. Coonrod, Xiaoqiu Liu, Xuesen Zhang
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Breast cancer
Tamoxifen-resistance
PAD2
Docetaxel
Online Access:http://link.springer.com/article/10.1186/s13046-019-1404-8

Internet

http://link.springer.com/article/10.1186/s13046-019-1404-8

Similar Items